Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 841-845

  Marey, Hatem M ^a   Ellakwa, Amin F ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Bevacizumab; Intravitreal injection; Mitomycin C; Neovascular glaucoma; Subscleral trabeculectomy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; MITOMYCIN C;

ADULT; AGED; ARTICLE; CASE STUDY; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DIABETIC RETINOPATHY; EYE SYNECHIA; FEMALE; FILTERING OPERATION; HUMAN; INTRAOCULAR PRESSURE; IRIS BLOOD VESSEL; IRIS NEOVASCULARIZATION; LASER COAGULATION; MALE; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); RECURRENT DISEASE; RETINA ISCHEMIA; RETROSPECTIVE STUDY; TRABECULECTOMY; VISUAL ACUITY;

EID: 79959857518     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S21453     Document Type: Article

References (21)

1. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular oedema. Ophthalmology. 2005;112: 806-816.
2. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol. 2007;143:510-512.
3. Sivack-Callcott JA, O'Day DM, Gass DM, et al. Evidence based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1776.
4. Allingham RA, Damji KF, Freedman S, et al, editors. Glaucomas associated with disorders of the retina, vitreous and choroids. In: Shields' Textbook of Glaucoma, 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2005.
5. Moraczewski AL, Lee RK, Palmberg PF, et al. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009;93:589-593.
6. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713-718.
7. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
8. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-750.
9. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-149.
10. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142(6):1054-1056.
11. Mason JO, Albert MA, Mays A, et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina. 2006;26: 839-841.
12. Paula JS, Jorge R, Costa RA, et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovasculariszation in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556-557.
13. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-146.
14. Ghanem AA, El-Kannishy AM, El-Wehidy AS, et al. Intravitreal bevacizumab (Avastin) as an adjuvant treatment in cases of neovascular glaucoma. Middle East Afr J Ophthalmol. 2009;16:75-79.
15. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovessels after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalomol. 2006;142:155-158.
16. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther. 2007;23: 487-491.
17. Parrish R, Herscher J. Eyes with end-stage neovascular glaucoma: natural history following successful modified filtering operation. Arch Ophthalmol. 1983;101:745-746.
18. Elgin U, Berker N, Batman A, et al. Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma. 2006;15:466-470.
19. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007;39:121-122.
20. De Moraes CG, Facio AC, Costa JH, et al. Intracameral bevacizumab and mitomycin C trabeculectomy for eyes with neovascular glaucoma: a case series. J Ocul Biol Dis Infor. 2009;2:40-46.
21. Chen CH, Lai IC, Wu PC, et al. Adjunctive intravitreal bevacizumabcombined trabeculectomy versus =20 trabeculectomy alone in the treatment of neovascular glaucoma. J Ocul Pharmacol Ther. 2010;26: 111-118.